Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Intraductal, Noninfiltrating | 6 | 2020 | 936 | 1.320 |
Why?
|
Mammography | 17 | 2024 | 2427 | 1.140 |
Why?
|
Melanoma | 24 | 2022 | 5697 | 1.050 |
Why?
|
Breast Neoplasms | 23 | 2024 | 21029 | 0.830 |
Why?
|
Skin Neoplasms | 19 | 2022 | 5799 | 0.750 |
Why?
|
SEER Program | 6 | 2020 | 1530 | 0.680 |
Why?
|
Early Detection of Cancer | 16 | 2024 | 3202 | 0.650 |
Why?
|
Models, Statistical | 14 | 2024 | 5075 | 0.600 |
Why?
|
Interferon-alpha | 8 | 2022 | 919 | 0.500 |
Why?
|
Simian immunodeficiency virus | 9 | 2014 | 805 | 0.460 |
Why?
|
Mass Screening | 11 | 2024 | 5422 | 0.460 |
Why?
|
Risk Assessment | 12 | 2021 | 24102 | 0.430 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1096 | 0.420 |
Why?
|
Health Status Disparities | 1 | 2023 | 1829 | 0.390 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 6 | 2013 | 538 | 0.380 |
Why?
|
Viremia | 7 | 2014 | 707 | 0.290 |
Why?
|
Computer Simulation | 8 | 2021 | 6218 | 0.280 |
Why?
|
Carboplatin | 5 | 2015 | 789 | 0.230 |
Why?
|
Schistosomiasis mansoni | 3 | 2011 | 94 | 0.230 |
Why?
|
Breast Self-Examination | 1 | 2003 | 33 | 0.230 |
Why?
|
Macaca mulatta | 9 | 2014 | 2316 | 0.220 |
Why?
|
Survival Analysis | 9 | 2019 | 10185 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 11713 | 0.210 |
Why?
|
Neoplasm Staging | 14 | 2022 | 11152 | 0.200 |
Why?
|
Niacinamide | 5 | 2015 | 414 | 0.200 |
Why?
|
Survival Rate | 8 | 2021 | 12810 | 0.190 |
Why?
|
United States | 20 | 2024 | 72448 | 0.180 |
Why?
|
Prognosis | 15 | 2021 | 29661 | 0.180 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2022 | 102 | 0.180 |
Why?
|
Phenylurea Compounds | 5 | 2015 | 529 | 0.180 |
Why?
|
Aged | 35 | 2024 | 169143 | 0.180 |
Why?
|
Disease Susceptibility | 4 | 2019 | 1792 | 0.170 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2018 | 296 | 0.170 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 886 | 0.170 |
Why?
|
Middle Aged | 41 | 2024 | 220359 | 0.170 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2002 | 220 | 0.170 |
Why?
|
Paclitaxel | 5 | 2015 | 1737 | 0.170 |
Why?
|
Early Diagnosis | 1 | 2004 | 1180 | 0.170 |
Why?
|
Models, Biological | 3 | 2018 | 9468 | 0.170 |
Why?
|
Melanoma, Amelanotic | 1 | 2019 | 19 | 0.160 |
Why?
|
Female | 53 | 2024 | 391246 | 0.160 |
Why?
|
Adjuvants, Immunologic | 2 | 2022 | 1039 | 0.160 |
Why?
|
Population Surveillance | 2 | 2014 | 2608 | 0.150 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1060 | 0.150 |
Why?
|
HIV Envelope Protein gp160 | 3 | 2014 | 92 | 0.150 |
Why?
|
Incidence | 8 | 2024 | 21391 | 0.150 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 3 | 2014 | 119 | 0.150 |
Why?
|
Disease Progression | 6 | 2022 | 13505 | 0.150 |
Why?
|
Adult | 36 | 2024 | 220007 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2022 | 9278 | 0.140 |
Why?
|
Nevus | 1 | 2019 | 205 | 0.140 |
Why?
|
False Positive Reactions | 5 | 2024 | 956 | 0.140 |
Why?
|
Disease-Free Survival | 11 | 2019 | 6831 | 0.140 |
Why?
|
Aged, 80 and over | 16 | 2021 | 58980 | 0.130 |
Why?
|
Humans | 65 | 2024 | 760613 | 0.130 |
Why?
|
Herpes Genitalis | 2 | 2009 | 142 | 0.130 |
Why?
|
Chronic Disease | 4 | 2007 | 9288 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12531 | 0.130 |
Why?
|
Immunity, Mucosal | 3 | 2014 | 481 | 0.130 |
Why?
|
Herpesvirus 2, Human | 2 | 2009 | 191 | 0.130 |
Why?
|
HIV-1 | 7 | 2014 | 6849 | 0.130 |
Why?
|
Sputum | 1 | 2017 | 503 | 0.120 |
Why?
|
Schistosoma mansoni | 3 | 2011 | 156 | 0.120 |
Why?
|
Receptors, Estrogen | 3 | 2024 | 2210 | 0.120 |
Why?
|
Gene Products, gag | 2 | 2014 | 312 | 0.120 |
Why?
|
Selenium | 2 | 2017 | 416 | 0.120 |
Why?
|
Direct Service Costs | 1 | 2014 | 60 | 0.120 |
Why?
|
Cyclosporins | 2 | 2004 | 216 | 0.120 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4167 | 0.110 |
Why?
|
Vaccination | 4 | 2014 | 3359 | 0.110 |
Why?
|
Immunity | 1 | 2019 | 998 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 7 | 2018 | 6544 | 0.100 |
Why?
|
Age Factors | 6 | 2024 | 18413 | 0.100 |
Why?
|
Vaccines, Attenuated | 1 | 2013 | 314 | 0.100 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2022 | 2053 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2019 | 10343 | 0.100 |
Why?
|
Heterosexuality | 1 | 2013 | 294 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2019 | 3530 | 0.100 |
Why?
|
Gene Expression Profiling | 4 | 2022 | 9406 | 0.100 |
Why?
|
Lymphocyte Subsets | 2 | 2010 | 310 | 0.100 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2013 | 590 | 0.100 |
Why?
|
Young Adult | 13 | 2022 | 58748 | 0.090 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 368 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 518 | 0.090 |
Why?
|
Antineoplastic Agents | 6 | 2019 | 13627 | 0.080 |
Why?
|
Mucous Membrane | 2 | 2010 | 657 | 0.080 |
Why?
|
Listeria monocytogenes | 1 | 2011 | 248 | 0.080 |
Why?
|
Integrins | 1 | 2013 | 839 | 0.080 |
Why?
|
Family Characteristics | 1 | 2013 | 1001 | 0.080 |
Why?
|
Public Health | 1 | 2002 | 2653 | 0.080 |
Why?
|
Benzenesulfonates | 1 | 2009 | 165 | 0.080 |
Why?
|
Recombinant Proteins | 5 | 2017 | 6538 | 0.080 |
Why?
|
RNA, Small Interfering | 2 | 2009 | 3442 | 0.080 |
Why?
|
AIDS Vaccines | 1 | 2014 | 895 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 1189 | 0.070 |
Why?
|
Mortality | 4 | 2024 | 2916 | 0.070 |
Why?
|
Adenoviridae | 1 | 2011 | 1084 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2024 | 7475 | 0.070 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5251 | 0.070 |
Why?
|
HIV Infections | 7 | 2013 | 17165 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2012 | 972 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 2013 | 0.070 |
Why?
|
Cancer Vaccines | 1 | 2014 | 1046 | 0.070 |
Why?
|
Viral Load | 6 | 2011 | 3322 | 0.070 |
Why?
|
Male | 25 | 2022 | 359718 | 0.070 |
Why?
|
Viral Vaccines | 1 | 2011 | 596 | 0.060 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2009 | 640 | 0.060 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39262 | 0.060 |
Why?
|
Sensitivity and Specificity | 6 | 2014 | 14661 | 0.060 |
Why?
|
Adolescent | 10 | 2022 | 87809 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2119 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 629 | 0.060 |
Why?
|
Massachusetts | 1 | 2018 | 8803 | 0.060 |
Why?
|
Time Factors | 8 | 2021 | 40139 | 0.060 |
Why?
|
Genes, MDR | 1 | 2004 | 36 | 0.060 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2882 | 0.060 |
Why?
|
Biometry | 1 | 2007 | 559 | 0.060 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 1088 | 0.060 |
Why?
|
HIV Core Protein p24 | 1 | 2004 | 245 | 0.060 |
Why?
|
Viral Envelope Proteins | 1 | 2007 | 638 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2019 | 4902 | 0.050 |
Why?
|
Drug Resistance, Multiple | 1 | 2004 | 254 | 0.050 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 265 | 0.050 |
Why?
|
DNA Methylation | 1 | 2017 | 4372 | 0.050 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 558 | 0.050 |
Why?
|
Meta-Analysis as Topic | 1 | 2008 | 1376 | 0.050 |
Why?
|
Virus Replication | 5 | 2011 | 2432 | 0.050 |
Why?
|
Sex Factors | 1 | 2016 | 10546 | 0.050 |
Why?
|
Models, Theoretical | 2 | 2004 | 3562 | 0.050 |
Why?
|
Vincristine | 1 | 2004 | 1038 | 0.050 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2803 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2009 | 3610 | 0.050 |
Why?
|
Breast | 2 | 2024 | 1963 | 0.050 |
Why?
|
Immunity, Innate | 1 | 2013 | 3047 | 0.050 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13262 | 0.050 |
Why?
|
Oximes | 1 | 2022 | 306 | 0.050 |
Why?
|
Quality of Life | 1 | 2022 | 13308 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2013 | 4550 | 0.050 |
Why?
|
Receptor, erbB-2 | 2 | 2024 | 2554 | 0.040 |
Why?
|
Dietary Supplements | 1 | 2013 | 3392 | 0.040 |
Why?
|
Health Planning | 1 | 2002 | 232 | 0.040 |
Why?
|
Vaccines, Synthetic | 2 | 2014 | 617 | 0.040 |
Why?
|
Cytarabine | 3 | 2009 | 696 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2020 | 169 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 642 | 0.040 |
Why?
|
Double-Blind Method | 4 | 2015 | 12427 | 0.040 |
Why?
|
Cohort Studies | 2 | 2020 | 41337 | 0.040 |
Why?
|
Treatment Outcome | 9 | 2021 | 64981 | 0.040 |
Why?
|
Mitotic Index | 1 | 2019 | 161 | 0.040 |
Why?
|
Vagina | 3 | 2010 | 837 | 0.040 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2002 | 1351 | 0.040 |
Why?
|
Hair Color | 1 | 2019 | 131 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 4 | 2013 | 4353 | 0.040 |
Why?
|
Epidemiologic Research Design | 1 | 2002 | 368 | 0.040 |
Why?
|
Probability | 1 | 2003 | 2475 | 0.040 |
Why?
|
Nuclear Receptor Coactivator 3 | 1 | 2017 | 46 | 0.040 |
Why?
|
Doxorubicin | 1 | 2004 | 2208 | 0.040 |
Why?
|
History, 21st Century | 1 | 2024 | 1575 | 0.040 |
Why?
|
Skin Ulcer | 1 | 2019 | 129 | 0.040 |
Why?
|
RGS Proteins | 1 | 2017 | 75 | 0.040 |
Why?
|
Daunorubicin | 2 | 2009 | 155 | 0.040 |
Why?
|
Administration, Intravaginal | 2 | 2009 | 151 | 0.040 |
Why?
|
Mutation | 3 | 2022 | 29957 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8512 | 0.040 |
Why?
|
Neoplasm Invasiveness | 2 | 2018 | 3618 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4899 | 0.040 |
Why?
|
Pyridones | 1 | 2022 | 792 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 7850 | 0.040 |
Why?
|
Dexamethasone | 1 | 2004 | 1927 | 0.030 |
Why?
|
Pyridines | 1 | 2009 | 2879 | 0.030 |
Why?
|
Infant | 2 | 2016 | 36053 | 0.030 |
Why?
|
Antiviral Agents | 1 | 2009 | 3061 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2007 | 3142 | 0.030 |
Why?
|
Child, Preschool | 2 | 2016 | 42056 | 0.030 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2020 | 733 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 26179 | 0.030 |
Why?
|
History, 20th Century | 1 | 2024 | 2773 | 0.030 |
Why?
|
Osteopontin | 1 | 2017 | 302 | 0.030 |
Why?
|
Interleukin-4 | 2 | 2011 | 1130 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2004 | 1894 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1827 | 0.030 |
Why?
|
Gene Products, nef | 1 | 2014 | 100 | 0.030 |
Why?
|
G(M2) Ganglioside | 1 | 2014 | 15 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5508 | 0.030 |
Why?
|
Child | 3 | 2022 | 79799 | 0.030 |
Why?
|
Gene Products, rev | 1 | 2013 | 29 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2024 | 2001 | 0.030 |
Why?
|
Liposomes | 2 | 2009 | 777 | 0.030 |
Why?
|
Myelodysplastic Syndromes | 1 | 2004 | 1401 | 0.030 |
Why?
|
Risk Factors | 5 | 2021 | 74333 | 0.030 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 2013 | 153 | 0.030 |
Why?
|
Immune Tolerance | 1 | 2002 | 2299 | 0.030 |
Why?
|
Receptors, HIV | 1 | 2013 | 159 | 0.030 |
Why?
|
Antibodies, Neutralizing | 2 | 2014 | 1933 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2004 | 1629 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1895 | 0.030 |
Why?
|
Feces | 2 | 2011 | 1455 | 0.030 |
Why?
|
Genes, ras | 1 | 2015 | 654 | 0.030 |
Why?
|
Animals | 11 | 2014 | 167960 | 0.030 |
Why?
|
Fusion Proteins, gag-pol | 1 | 2011 | 7 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2018 | 989 | 0.020 |
Why?
|
Administration, Rectal | 1 | 2011 | 70 | 0.020 |
Why?
|
Remission Induction | 2 | 2009 | 2392 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2002 | 3709 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2019 | 1266 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2015 | 567 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 123 | 0.020 |
Why?
|
Chemoprevention | 1 | 2013 | 326 | 0.020 |
Why?
|
Dacarbazine | 1 | 2014 | 560 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2019 | 2138 | 0.020 |
Why?
|
Gene Silencing | 2 | 2009 | 1512 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3113 | 0.020 |
Why?
|
Pneumonectomy | 1 | 2017 | 1111 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2014 | 604 | 0.020 |
Why?
|
Eggs | 1 | 2011 | 183 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 618 | 0.020 |
Why?
|
Coculture Techniques | 1 | 2013 | 1342 | 0.020 |
Why?
|
Multivariate Analysis | 3 | 2010 | 12159 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15679 | 0.020 |
Why?
|
Topotecan | 1 | 2009 | 132 | 0.020 |
Why?
|
Prospective Studies | 3 | 2022 | 54306 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3844 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2013 | 870 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2011 | 1385 | 0.020 |
Why?
|
Alopecia | 1 | 2013 | 414 | 0.020 |
Why?
|
Aminoglycosides | 1 | 2009 | 163 | 0.020 |
Why?
|
Immunization, Secondary | 1 | 2011 | 366 | 0.020 |
Why?
|
Constipation | 1 | 2013 | 561 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2014 | 1557 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1818 | 0.020 |
Why?
|
Mice, Inbred BALB C | 2 | 2009 | 6216 | 0.020 |
Why?
|
Immunophenotyping | 2 | 2004 | 1870 | 0.020 |
Why?
|
Internationality | 1 | 2013 | 1004 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2014 | 1300 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2019 | 10826 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1723 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 474 | 0.020 |
Why?
|
Mouth Mucosa | 1 | 2010 | 426 | 0.020 |
Why?
|
Antigens, Viral | 1 | 2011 | 980 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16932 | 0.020 |
Why?
|
RNA, Viral | 2 | 2007 | 2838 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2009 | 6498 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4108 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3802 | 0.020 |
Why?
|
Registries | 2 | 2013 | 8458 | 0.020 |
Why?
|
Prevalence | 1 | 2003 | 15686 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1544 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2020 | 3527 | 0.020 |
Why?
|
Autoimmunity | 1 | 2014 | 1370 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2019 | 80345 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 8055 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2852 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 666 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2017 | 3486 | 0.020 |
Why?
|
Rectum | 1 | 2010 | 895 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2014 | 20080 | 0.020 |
Why?
|
Sample Size | 1 | 2008 | 840 | 0.010 |
Why?
|
Genes, Viral | 1 | 2005 | 650 | 0.010 |
Why?
|
Genes, Essential | 1 | 2005 | 184 | 0.010 |
Why?
|
Mitoxantrone | 1 | 2004 | 149 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 2569 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2375 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2009 | 2222 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3157 | 0.010 |
Why?
|
Host-Pathogen Interactions | 1 | 2011 | 1447 | 0.010 |
Why?
|
Cell Adhesion Molecules | 1 | 2009 | 1602 | 0.010 |
Why?
|
Dendritic Cells | 1 | 2013 | 2725 | 0.010 |
Why?
|
Etoposide | 1 | 2004 | 630 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2013 | 3484 | 0.010 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2002 | 133 | 0.010 |
Why?
|
Perforin | 1 | 2002 | 167 | 0.010 |
Why?
|
Eosinophilia | 1 | 2007 | 559 | 0.010 |
Why?
|
Interferons | 1 | 2005 | 705 | 0.010 |
Why?
|
Cervix Uteri | 1 | 2005 | 582 | 0.010 |
Why?
|
Benchmarking | 1 | 2008 | 1044 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14494 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10553 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7587 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4571 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2005 | 2120 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12957 | 0.010 |
Why?
|
Intestinal Mucosa | 1 | 2010 | 3022 | 0.010 |
Why?
|
Macrophages | 1 | 2013 | 5745 | 0.010 |
Why?
|
Viral Proteins | 1 | 2005 | 1802 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2008 | 18137 | 0.010 |
Why?
|
Inflammation | 2 | 2010 | 10755 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2013 | 18955 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2002 | 755 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15286 | 0.010 |
Why?
|
Patient Selection | 1 | 2010 | 4279 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 25941 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2221 | 0.010 |
Why?
|
Recurrence | 1 | 2009 | 8483 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2002 | 1075 | 0.010 |
Why?
|
Cell Division | 1 | 2004 | 4463 | 0.010 |
Why?
|
Virus Diseases | 1 | 2002 | 720 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 2004 | 1810 | 0.010 |
Why?
|
HIV | 1 | 2002 | 1579 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2004 | 5496 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 9185 | 0.010 |
Why?
|
Research Design | 1 | 2008 | 6180 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15620 | 0.010 |
Why?
|
Mice | 2 | 2009 | 81209 | 0.010 |
Why?
|
Logistic Models | 1 | 2004 | 13312 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2008 | 8985 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2002 | 22052 | 0.000 |
Why?
|